Zydus Lifesciences Ltd Receives Approval from COFEPRIS of Mexico to Market Mamitra™, a Trastuzumab Biosimilar

Zydus Lifesciences Ltd has received approval from the Mexican regulatory authority COFEPRIS to market Mamitra™, a Trastuzumab biosimilar. The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2 overexpressing metastatic breast cancer (MBC), HER2 overexpressing early breast cancer (EBC) and advanced gastric cancer. Breast cancer is the most diagnosed cancer in Mexico. Zydus had developed and launched the Trastuzumab biosimilar in India under the brand name Vivitra in 2016. The company has been bridging the unmet need for affordable therapies in the fight against cancer in India with twelve lifesaving biosimilars already launched in the market.